Department of Cardiothoracic Surgery, Erasmus University Medical Centre, Rotterdam, Netherlands.
Department of Paediatrics, Div. of Cardiology, Erasmus University Medical Centre, Rotterdam, Netherlands.
Eur J Cardiothorac Surg. 2023 Sep 7;64(3). doi: 10.1093/ejcts/ezad284.
To support clinical decision-making in children with aortic valve disease, by compiling the available evidence on outcome after paediatric aortic valve repair (AVr).
A systematic review of literature reporting clinical outcome after paediatric AVr (mean age at surgery <18 years) published between 1 January 1990 and 23 December 2021 was conducted. Early event risks, late event rates and time-to-event data were pooled. A microsimulation model was employed to simulate the lives of individual children, infants and neonates following AVr.
Forty-one publications were included, encompassing 2 623 patients with 17 217 patient-years of follow-up (median follow-up: 7.3 years; range: 1.0-14.4 years). Pooled mean age during repair for aortic stenosis in children (<18 years), infants (<1 year) or neonates (<30 days) was 5.2 ± 3.9 years, 35 ± 137 days and 11 ± 6 days, respectively. Pooled early mortality after stenosis repair in children, infants and neonates, respectively, was 3.5% (95% confidence interval: 1.9-6.5%), 7.4% (4.2-13.0%) and 10.7% (6.8-16.9%). Pooled late reintervention rate after stenosis repair in children, infants and neonates, respectively, was 3.31%/year (1.66-6.63%/year), 6.84%/year (3.95-11.83%/year) and 6.32%/year (3.04-13.15%/year); endocarditis 0.07%/year (0.03-0.21%/year), 0.23%/year (0.07-0.71%/year) and 0.49%/year (0.18-1.29%/year); and valve thrombosis 0.05%/year (0.01-0.26%/year), 0.15%/year (0.04-0.53%/year) and 0.19%/year (0.05-0.77%/year). Microsimulation-based mean life expectancy in the first 20 years for children, infants and neonates with aortic stenosis, respectively, was 18.4 years (95% credible interval: 18.1-18.7 years; relative survival compared to the matched general population: 92.2%), 16.8 years (16.5-17.0 years; relative survival: 84.2%) and 15.9 years (14.8-17.0 years; relative survival: 80.1%). Microsimulation-based 20-year risk of reintervention in children, infants and neonates, respectively, was 75.2% (72.9-77.2%), 53.8% (51.9-55.7%) and 50.8% (47.0-57.6%).
Long-term outcomes after paediatric AVr for stenosis are satisfactory and dependent on age at surgery. Despite a high hazard of reintervention for valve dysfunction and slightly impaired survival relative to the general population, AVr is associated with low valve-related event occurrences and should be considered in children with aortic valve disease.
通过汇集儿童主动脉瓣修复(AVr)后结局的现有证据,为儿童主动脉瓣疾病的临床决策提供支持。
系统检索了 1990 年 1 月 1 日至 2021 年 12 月 23 日期间发表的关于儿科 AVr(手术时年龄<18 岁)临床结局的文献。汇总了早期事件风险、晚期事件发生率和生存时间数据。采用微模拟模型模拟 AVr 后个体儿童、婴儿和新生儿的生活。
共纳入 41 篇文献,包括 2623 例患者,17017 例患者年的随访(中位随访时间:7.3 年;范围:1.0-14.4 年)。儿童(<18 岁)、婴儿(<1 岁)和新生儿(<30 天)主动脉瓣狭窄修复时的平均修复年龄分别为 5.2±3.9 岁、35±137 天和 11±6 天。儿童、婴儿和新生儿主动脉瓣狭窄修复后的早期死亡率分别为 3.5%(95%置信区间:1.9-6.5%)、7.4%(4.2-13.0%)和 10.7%(6.8-16.9%)。儿童、婴儿和新生儿主动脉瓣狭窄修复后晚期再次介入治疗率分别为 3.31%/年(1.66-6.63%/年)、6.84%/年(3.95-11.83%/年)和 6.32%/年(3.04-13.15%/年);心内膜炎为 0.07%/年(0.03-0.21%/年)、0.23%/年(0.07-0.71%/年)和 0.49%/年(0.18-1.29%/年);瓣膜血栓形成率为 0.05%/年(0.01-0.26%/年)、0.15%/年(0.04-0.53%/年)和 0.19%/年(0.05-0.77%/年)。基于微模拟的儿童、婴儿和新生儿主动脉瓣狭窄患者在头 20 年的平均预期寿命分别为 18.4 岁(95%可信区间:18.1-18.7 岁;与匹配的一般人群相比,相对生存率为 92.2%)、16.8 岁(16.5-17.0 岁;相对生存率为 84.2%)和 15.9 岁(14.8-17.0 岁;相对生存率为 80.1%)。儿童、婴儿和新生儿再次介入治疗的 20 年风险分别为 75.2%(72.9-77.2%)、53.8%(51.9-55.7%)和 50.8%(47.0-57.6%)。
儿童主动脉瓣狭窄修复后的长期结局令人满意,且取决于手术时的年龄。尽管因瓣膜功能障碍而再次介入的风险较高,且与一般人群相比生存能力略有受损,但 AVr 与较低的瓣膜相关事件发生率相关,应在患有主动脉瓣疾病的儿童中考虑使用。